Company News
New Hope for SMA Patients: Nusinersen Sodium
Discover how Nusinersen Sodium Injection is transforming the lives of SMA patients worldwide with its proven efficacy and comprehensive care services.
A Remarkable Recovery: Treating Relapsed B-ALL with CAR-T Therapy
Bioocus Medical Group specializes in providing advanced cellular and gene therapies for patients facing complex medical challenges. We recently had the honor of treating Shakib Haytham Ghassan Abu-Hamdan, a 16-year-old from Jordan diagnosed with relapsed B cell Acute Lymphoblastic Leukemia (B-ALL). This article highlights Shakib’s treatment journey and how CD22-Targeted Chimeric Antigen Receptor T (CAR-T) Cell Therapy transformed his life.
BIOOCUS Introduces Nusinersen Sodium Injection: A Breakthrough in SMA Treatment
Spinal Muscular Atrophy (SMA) is a rare and devastating genetic neuromuscular disorder that affects individuals of all ages, leading to progressive muscle weakness and loss of motor function. For years, patients and their families have faced limited treatment options. However, a revolutionary therapy has emerged, offering new hope and transforming the lives of those affected by SMA.
Bringing Hope to a Brave Fighter: Advanced Cancer Treatment at Bioocus Medical Group
At Bioocus Medical Group, we are proud to be treating a courageous patient from Pakistan who is battling Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL). This aggressive form of cancer requires advanced treatment, and we are committed to providing the best possible care through our cutting-edge therapies and compassionate support.
Bringing Hope to a Young Life: Advanced Leukemia Treatment at Bioocus Medical Group
At Bioocus Medical Group, we are dedicated to delivering cutting-edge cellular and gene therapies to patients worldwide. The story of Shakib Haytham Ghassan Abu-Hamdan, a 16-year-old boy from Jordan, exemplifies our commitment. Shakib is currently undergoing treatment for relapsed B-cell acute lymphoblastic leukemia (B-ALL) at our Cellular and Gene Therapy (CGT) Center at Tianjin Cancer Hospital Airport Hospital.
Bringing Hope to Young Lives: Advanced Cancer Treatment at Bioocus Medical Group
At Bioocus Medical Group, we are committed to delivering cutting-edge cellular and gene therapies to patients worldwide. A compelling example of this dedication is Emin, an 8-year-old boy from Russia, currently receiving treatment for Stage IV neuroblastoma at our Cellular and Gene Therapy (CGT) Center in Tianjin Cancer Hospital Airport Hospital.
Academic Breakthrough | Lu Daopei Medical Team Publishes Groundbreaking Clinical Study in the British Journal of Haematology
The Lu Daopei Medical Team, led by Dr. Cao Xingyu and Prof. Lu Peihua, has published an important clinical research paper in the British Journal of Haematology (Impact Factor 5.1). The study investigates the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) after autologous CD7 CAR-T therapy for refractory and relapsed T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (R/R T-ALL/T-LBL).
Multi-Center Study Shows Good Prognosis for Hematologic Malignancy Patients Undergoing MMUD Allogeneic Stem Cell Transplant with ATG
A large multi-center study in China reveals positive outcomes for patients with hematologic malignancies undergoing mismatched unrelated donor (MMUD) stem cell transplants with ATG for GVHD prevention
Patient Story: High-Risk B-ALL, Bone Marrow Transplant at 9 Months, Two Years Later—A Healthy Start for a Young Fighter
A 9-month-old child, diagnosed with high-risk Acute B Lymphoblastic Leukemia (B-ALL), undergoes a successful bone marrow transplant. Two years later, the child is thriving and ready for kindergarten.
Understanding Thalassemia: A Comprehensive Guide to Alpha and Beta Forms
Thalassemia is more than one disease. This guide explores both alpha and beta thalassemia, their causes, symptoms, and the latest treatment options available at BIOOCUS International Medical Center.
Dr. Lu Peihua Presents Breakthrough in CAR-T Therapy at the 29th APBMT Annual Meeting
At the 29th Asia-Pacific Blood and Marrow Transplantation (APBMT) Annual Meeting, Dr. Lu Peihua delivered a keynote address on the success of CAR-T cell therapy in China. Her team’s real-world data from clinical practice received international acclaim, showcasing their contributions to the treatment of blood malignancies.
ASH 2024: Lu Daopei Team Showcases 13 Research Achievements in Hematology
At the upcoming ASH 2024 conference, the Lu Daopei Hospital medical team will present 13 groundbreaking research findings, highlighting advancements in hematology and the potential of CAR-T therapy, reaffirming their commitment to improving patient outcomes.